China Universal Asset Management Company’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $26.2K | Buy |
2,966
+36
| +1% | +$318 | ﹤0.01% | 445 |
|
|
2025
Q1 | $31.5K | Sell |
2,930
-30
| -1% | -$323 | ﹤0.01% | 443 |
|
|
2024
Q4 | $37.9K | Buy |
2,960
+498
| +20% | +$6.38K | ﹤0.01% | 463 |
|
|
2024
Q3 | $67.9K | Buy |
2,462
+964
| +64% | +$26.6K | 0.01% | 378 |
|
|
2024
Q2 | $43.4K | Sell |
1,498
-945
| -39% | -$27.4K | 0.01% | 366 |
|
|
2024
Q1 | $109K | Buy |
2,443
+986
| +68% | +$44K | 0.01% | 366 |
|
|
2023
Q4 | $56.5K | Buy |
1,457
+1,135
| +352% | +$44K | 0.01% | 360 |
|
|
2023
Q3 | $9.46K | Buy |
322
+158
| +96% | +$4.64K | ﹤0.01% | 349 |
|
|
2023
Q2 | $10.4K | Sell |
164
-5
| -3% | -$317 | ﹤0.01% | 314 |
|
|
2023
Q1 | $7.98K | Buy |
169
+42
| +33% | +$1.98K | ﹤0.01% | 322 |
|
|
2022
Q4 | $8.79K | Buy |
127
+11
| +9% | +$761 | ﹤0.01% | 240 |
|
|
2022
Q3 | $17K | Buy |
+116
| New | +$17K | 0.01% | 165 |
|